Inactive Instrument

Kolinpharma S.p.A.

KIP

IT0005322950

Kolinpharma S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2020

March 28, 2021

Kolinpharma S.P.A. Announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was EUR 9.398 million compared to EUR 10.507 million a year ago. Net income was EUR 642,372 compared to EUR 591,320 a year ago.

Latest news about Kolinpharma S.p.A.

Kolinpharma presents supplement; patent application already filed	30/08/23	AN
Kolinpharma increases turnover in the first half of the year	28/07/23	AN
Igea Holding raises offer to take over Kolinpharma shares	28/07/23	AN
Kolinpharma suspends buyback plan after takeover bid by Igea Holding	28/06/23	AN
Kolinpharma S.p.A.'s Equity Buyback announced on May 15, 2023, has suspended.	27/06/23	CI
Kolinpharma continues with share buyback	22/06/23	AN
Kolinpharma S.p.A. commences an Equity Buyback Plan under the authorization approved on April 21, 2023.	14/05/23	CI
Kolinpharma, over 200,000 medical prescriptions in first quarter	04/05/23	AN
Kolinpharma, shareholders' meeting confirms board of directors	21/04/23	AN
Kolinpharma S.p.A.'s Equity Buyback announced on April 28, 2022, has expired.	20/04/23	CI
Europeans up; Tenaris at bottom on Mib.	14/04/23	AN
Kolinpharma, profit halves in 2022 but revenue rises	22/03/23	AN
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23	CI
Kolinpharma, prescriptions and whistleblowers grow in fourth quarter	07/02/23	AN
Kolinpharma goes ahead with buybacks of its own common stock	17/01/23	AN
Kolinpharma goes ahead with share buybacks	11/01/23	AN
Kolinpharma purchased its own shares for EUR22,000 approx.	10/01/23	AN
Kolinpharma purchased its own shares for EUR22,000 approx.	10/01/23	AN
Kolinpharma purchased its own shares for about EUR19,000	28/12/22	AN
Kolinpharma S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	28/09/22	CI
Kolinpharma S.p.A.'s Equity Buyback announced on February 25, 2022, has expired.	27/04/22	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 28, 2022.	27/04/22	CI
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	28/03/22	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 29, 2021.	25/02/22	CI
Kolinpharma S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021	27/09/21	CI

Chart Kolinpharma S.p.A.

Duration

Period

More charts

Company Profile

Kolinpharma SpA is an Italy-based company specialized in the pharmaceutical industry. The Company offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.69%	728B
NOVO NORDISK A/S	+33.78%	603B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	279B
ASTRAZENECA PLC	+15.85%	244B
NOVARTIS AG	+7.65%	207B
ROCHE HOLDING AG	-5.56%	205B
PFIZER, INC.	-0.35%	163B

Other Pharmaceuticals